Skip to main content
SpringerLink
Log in

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents, Vol. IX. IARC Scientific Publication, Lyon

    Google Scholar 

  2. Kleihues P, Soylemezoglu F, Schauble B et al (1995) Histopathology, classification, and grading of gliomas. Glia 15:211–221

    Article  PubMed  CAS  Google Scholar 

  3. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25:867–890, vii

    Article  PubMed  Google Scholar 

  4. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  5. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  PubMed  CAS  Google Scholar 

  6. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740–745

    Article  PubMed  CAS  Google Scholar 

  7. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    CAS  Google Scholar 

  8. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266

    Article  PubMed  CAS  Google Scholar 

  9. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771

    CAS  Google Scholar 

  10. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012

    CAS  Google Scholar 

  11. Taillibert S, Hoang-Xuan K, Guiu B et al (2010) Bevacizumab (b) with irinotecan (i) in recurrent glioblastoma (GBM): a national retrospective cohort of the ANOCEF (association des Neurooncologues d’expression française) group. Ann Oncol 21:viii329 (Abstract 1056P)

    Article  Google Scholar 

  12. Grude F, Campone M, Soulie P et al (2010) Bevacizumab and irinotecan in recurrent malignant glioma: Results of a French retrospective cohort study omit of 264 patients in real practice! Ann Oncol 21:viii329 (Abstract 1058P)

    Article  Google Scholar 

  13. Gil JM, De las Penas R, Reynes G et al (2010) Bevacizumab plus irinotecan in recurrent malignant glioma showed high overall survival in a retrospective study. Neuro Oncol 12:iv1–iv136:53 (Abst NO-73)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Service, Institut Català d’Oncologia Germans Trias i Pujol, Carretera Canyet, s/n, ES-08916, Badalona, Barcelona, Spain

    Carmen Balañá, Olatz Etxaniz, Cristina Bugés & Alex Martínez

Authors
  1. Carmen Balañá
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olatz Etxaniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Bugés
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alex Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Balañá.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balañá, C., Etxaniz, O., Bugés, C. et al. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?. Clin Transl Oncol 13, 209–210 (2011). https://doi.org/10.1007/s12094-011-0642-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0642-9

Keywords

Search

Navigation